Abstract
To examine the effect of pravastatin administration on striated muscle ultrastructure, 10 BalbC mice were given pravastatin 40 mg/kg/day for 3 weeks. At the end of the study, blood was withdrawn for evaluation of the serum creatine phospho-kinase (CPK) level and the muscles of the hind legs, as well as the heart and liver of the animals were examined with a light and transmission electron microscope. After treatment with pravastatin the results showed a 101% increase in serum CPK level in comparison to untreated controls. Hematoxillin-eosin stained tissues of pravastatin treated mice did not show any abnormal findings. While the ultrastructure of the heart and liver of the treated animals appeared normal, the muscle fibers showed a marked alterations of the mitochondria, which were increased in size compared to those of the controls. The cristae were heavily damaged and even completely destructed, giving the mitochondria appearance of empty vacuoles. The findings are in favor of a specificity of pravastatin for striated muscles.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arita S, Kasraie A, Une S, Ohtsuka S, Atyia A, Shelvin L and Mullen Y (1998) Pravastatin and low-dose cyclosporine treatment prevent islet allograft rejection in mice. Transplant Proc 30: 522.
Decoulx E, Millaire A, de-Groote P, Mahieux G and Ducloux G (1993) Rhabdomyolysis caused by pravastatin and type 1 macro-creatinine kinase. Ann Cardiol Angeiol Paris 42: 267–269.
Diaz-Zagoya JC, Asenjo-Baron JC, Cardenas-Vasquez R, Martinez F and Juarez-Oropeza MA (1999) Comparative toxicity of high doses of vastatins surrently used by clinicians, in CD-1 male mice fed with hypercholesterolemic diet. Life Sci 65: 947–956.
Flint OP, Masters BA, Gregg RF and Durham SK (1997) HMG-CoA reductase inhibitor-induced myotoxicity pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 145: 99–110.
Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ and Tamagawa H (1990) Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 87: 8931–8934.
Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T and Tsujita T (1993) Defetect of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 193: 263–273.
Gadbut AP, Caruso AP and Galper JB (1995) Diffirential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 27: 2397–2402.
Le Quintrec JS and Le Quintrec JL (1991) Drug induced myopathies. Bailliers Clin Rheumatol 5: 21–38.
Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D and Durham SK (1995) In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat myocytes. Toxicol Appl Pharmacoal 131: 163–174.
Mortensen SA, Leth A, Agner E and Rohde M (1997) Dose related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 18 (Suppl: S): 137144.
Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J et al. (1998) Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152: 99–106.
Pierno S, De Luca A, Tricarico D, Ferrannini E, Conte D, D'Alo G and Camerino DC (1992) Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle. Pharmacol Toxicol 71: 325–329.
Pierno S, De Luca A, Tricarico D, Roselli A, Natuzi F, Ferrannini E et al. (1995) Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 275: 1490–1496.
Raimondeau J, Le-Marec H, Chevallier JC and Bouhour JB (1992) Biological myolysis during combined feno brate-pravastatin therapy. Press Med 21: 663–664.
Reijneveld JC, Koot RW, Bredman JJ, Joles JA and Bar PR (1996) Diffirential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 39: 1028–1035.
Scalvini T, Marocolo D, Cerudelli B, Sleiman I, Balestrieri GP and Giustina G (1995) pravastatin-associated myopathy. Report of a case. Recenti Prog Med 86: 198–200.
Schalke BB, Schmidt B, Toyka K and Hartung HP (1992) Pravastatin associated inflammatory myopathy. N Eng J Med 327: 649–650.
Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Geremershausen JI et al. (1991) HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 257: 1225–1235.
Sugiyama S (1988) HMG Co reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats. Biochem Mol Biol Int 46: 923–931.
Ucar M, Mjorndal T and Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22: 441–457.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bergman, M., Salman, H., Djaldetti, M. et al. Ultrastructure of mouse striated muscle fibers following pravastatin administration. J Muscle Res Cell Motil 24, 417–420 (2003). https://doi.org/10.1023/A:1027367022415
Issue Date:
DOI: https://doi.org/10.1023/A:1027367022415